Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week High – Time to Buy?

Avalyn Pharma Inc. (NASDAQ:AVLN)’s stock price hit a new 52-week high on Tuesday . The stock traded as high as $33.32 and last traded at $32.73, with a volume of 171345 shares. The stock had previously closed at $31.00.

Wall Street Analysts Forecast Growth

AVLN has been the subject of several recent research reports. Morgan Stanley began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price for the company. Guggenheim started coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Evercore started coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective for the company. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group assumed coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Stock Up 5.0%

The company has a 50-day moving average price of $28.82.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Transactions at Avalyn Pharma

In other Avalyn Pharma news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the purchase, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 34.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jill Carroll bought 277,778 shares of Avalyn Pharma stock in a transaction on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 14.55% increase in their position. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.